Starpharma Holdings Ltd
PQ6
Company Profile
Business description
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating and VIRALEZE an antiviral nasal spray.
Contact
4-6 Southampton Crescent
Abbotsford
MelbourneVIC3067
AUST: +61 385322700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
32
Stocks News & Analysis
stocks
What next for the largest company on the ASX?
After a historic rally in 2024, what lies ahead for this overvalued banking titan?
stocks
Ask the analyst: Are IDP Education's woes temporary?
The global education services provider has gone from stock market darling to one of the ASX's weakest performers. What gives?
stocks
Is it time to buy the Magnificent Seven?
After the recent selloff, the bull market’s most in-demand stocks look much cheaper.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,013.30 | 46.70 | 0.59% |
| CAC 40 | 7,938.21 | 50.75 | -0.64% |
| DAX 40 | 22,567.14 | 109.27 | -0.48% |
| Dow JONES (US) | 40,813.57 | 537.36 | -1.30% |
| FTSE 100 | 8,542.56 | 1.59 | 0.02% |
| HKSE | 24,039.04 | 576.39 | 2.46% |
| NASDAQ | 17,303.01 | 345.44 | -1.96% |
| Nikkei 225 | 37,053.10 | 263.07 | 0.72% |
| NZX 50 Index | 12,266.25 | 57.20 | 0.47% |
| S&P 500 | 5,521.52 | 77.78 | -1.39% |
| S&P/ASX 200 | 7,789.70 | 40.60 | 0.52% |
| SSE Composite Index | 3,418.05 | 59.32 | 1.77% |